Interferon β therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis

Armando Sena, R. Pedrosa, V. Ferret-Sena, M. J. Cascais, R. Roque, C. Araújo, R. Couderc

Research output: Contribution to journalArticle

4 Citations (Scopus)


Serum ferritin levels have been found to be increased in patients with active progressive multiple sclerosis (MS). However, its levels are reported to be unchanged in stable and in active relapsing-remitting (RR) form of the disease. No research to date has assessed the influence of interferon β (IFN-β) on ferritin concentrations. In this study, serum ferritin levels were measured in 43 individuals with RR-MS and 38 age- and sex-matched control volunteers. There were no significant differences between controls and patients under stable and untreated conditions. In patients at 12 months after the beginning of IFN-β therapy, ferritin levels were higher in women and in men, in comparison with baseline (71.4 ± 58.6 vs 43.4 ± 29.9 ng/mL, P = 0.0006 and 216.0 ± 124.3 vs 127.8 ± 74.9 ng/mL, P = 0.0022, respectively). These results suggest that larger prospective studies are required to evaluate the role of serum ferritin in MS and its potential usefulness in monitoring responses to immunomodulatory therapies.

Original languageEnglish
Pages (from-to)857-859
Number of pages3
JournalMultiple Sclerosis
Issue number6
Publication statusPublished - 1 Jul 2008



  • Ferritin
  • Interferon beta
  • Iron metabolism
  • Multiple sclerosis

Cite this